Imugene's onCARlytics technology to feature in three abstracts at SITC 2022

Be the First to Comment Read
Sponsored

Imugene's onCARlytics technology to feature in three abstracts at SITC 2022

Follow us on Google News:
More on:
 Imugene's onCARlytics technology to feature in three abstracts at SITC 2022
Image source: Company Website

Highlights

  • Imugene Limited’s onCARlytics to be featured in three abstracts at the SITC annual meeting
  • The SITC 2022 meeting will be held from November 8 to 12 in Boston.
  • onCARlytics is a CD19-expressing oncolytic virus which enters tumor cells and forces them to express the CD19 protein on the cell surface, presenting a target for CD19-targeting therapies.

Imugene Limited (ASX:IMU), one of the eminent players in the biotech space, today revealed that its onCARlytics (CF33-CD19) oncolytic virus technology would be featured in three abstracts at the annual meeting of the Society for Immunotherapy of Cancer (SITC). The event is scheduled to be held from November 8-12 in Boston.

The SITC meeting is one of the most prestigious immunotherapy events on the calendar. This year, it will feature top-notch research presentations by various experts, oral and poster abstract presentations, many opportunities for networking, and discussions with members of the oncology community.

Abstract titles featuring Imugene's onCARlytics:
Title:
Combination immunotherapy using a novel chimeric oncolytic virus to redirect CD19 bispecific T cell engagers to target solid tumors
Title: CF33-CD19t oncolytic virus (onCARlytics) targets hepatocellular carcinoma (HCC) and in combination with Artemis® CD19 T cells results in significant tumor killing
Title:
CF33-CD19t oncolytic virus (onCARlytics) in combination with off-the-shelf allogeneic CyCART-19 T cells targeting de novo CD19+ solid tumors

What is onCARlytics?

onCARlytics is a novel combination immunotherapy to eradicate solid tumours, which are otherwise difficult to treat with CAR T therapy alone. Using this technology, CD19-expressing oncolytic virus is released to enter tumour cells and forces them to express the CD19 protein on the cell surface, presenting a target for CD19-targeting therapies. The technology has been licensed exclusively by Imugene from City of Hope, one of the largest cancer research and treatment organisations in the US.

Image Source: Company Website

Imugene’s shares were trading at AU$0.190 each on 6 October 2022.

 

Disclaimer

Featured Articles

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK